Numerous studies have reported overexpression of EGFR in 27–100% of solid tumors, including NSCLC, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), gastric-gastroesophageal junction cancer, urothelial cancer, clear cell renal cell carcinoma, hepatocellular carcinoma, glioblastoma, pancreatic cancer, and breast cancer, among others (4, 6, 10, 15). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.